ERBB2 and cancer: In support of this hypothesis, both EpCAM+ CTCs and Clusters > 2 increased after the first metastasis in HER2+ but not HR+ cancers (Figure 5b,d and Table S1), suggesting discrete evolutionary trajectories in CTC clustering between the receptor statuses.